Malaria Treatment in Pregnancy

Disclaimer: This information is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's circumstances and current clinical guidelines. Dosage recommendations are general and may need adjustment based on specific patient factors, local resistance patterns, and national guidelines.

Overview

• Definition: Malaria in pregnancy refers to infection with Plasmodium parasites in a pregnant woman. It is a major global health problem, particularly in endemic regions, significantly increasing both maternal and fetal morbidity and mortality.
• Epidemiology: Globally, an estimated 125 million pregnant women are at risk of malaria each year, with the vast majority in sub-Saharan Africa. P. falciparum is the most common and severe species, accounting for the highest burden of disease. Pregnant women are three times more likely to develop severe malaria compared to non-pregnant adults and are at increased risk of infection, especially primigravidae and HIV-infected women, due to pregnancy-induced alterations in immunity.
• Classification:
  • By Parasite Species: Plasmodium falciparum (most severe and common), P. vivax, P. ovale, P. malariae, and P. knowlesi.
  • By Clinical Severity:
    • Uncomplicated Malaria: Symptomatic malaria without signs of severe disease or vital organ dysfunction.
    • Severe Malaria: Defined by the presence of one or more severe manifestations (e.g., impaired consciousness, severe anemia, renal failure, acute respiratory distress, acidosis, shock, hypoglycemia, repeated generalized convulsions, significant bleeding, jaundice, high parasite density).

Pathophysiology

• Mechanism: Malaria infection involves the cyclical asexual reproduction of Plasmodium parasites within human red blood cells, leading to their lysis and systemic inflammation. In pregnancy, a unique pathological feature is the sequestration of P. falciparum-infected erythrocytes in the intervillous spaces of the placenta. These parasitized red blood cells (pRBCs) adhere to chondroitin sulfate A (CSA) expressed by syncytiotrophoblasts. This placental sequestration leads to:
  • Reduced blood flow and nutrient exchange to the fetus.
  • Inflammation within the placenta (intervillous inflammation).
  • Increased susceptibility of the pregnant woman to malaria due to altered immune responses (e.g., reduced cell-mediated immunity, altered cytokine profiles).
  • Increased parasite density and risk of severe malaria due to reduced splenic clearance and sequestration.
• Risk Factors:
  • Non-immune or partially immune pregnant women: Travelers to endemic areas, primigravidae (first pregnancy) are at highest risk due to lack of acquired immunity to placental malaria antigens.
  • HIV co-infection: Increases susceptibility to malaria, risk of higher parasite densities, and severe outcomes.
  • Geographic location: Living in or traveling to malaria-endemic areas.
  • Lack of effective prevention: Non-use of insecticide-treated bed nets (ITNs) or inadequate intermittent preventive treatment in pregnancy (IPTp).
  • Malnutrition/Anemia: Pre-existing conditions can exacerbate malaria severity.
• Protective Factors:
  • Use of insecticide-treated bed nets (ITNs): Reduces mosquito bites, particularly at night.
  • Indoor residual spraying (IRS): Community-level vector control.
  • Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP): In areas of moderate to high P. falciparum transmission.
  • Prompt diagnosis and effective treatment: Reduces parasite burden and prevents progression to severe disease.
  • Acquired immunity: Multigravidae in endemic areas develop some immunity, reducing the severity of disease in subsequent pregnancies.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Fever (often paroxysmal), chills, headache, fatigue, myalgia, arthralgia. These are often non-specific and can be confused with other pregnancy-related conditions or viral illnesses.
• Early Signs: Malaise, low-grade fever, headache, mild anemia.
• Advanced Signs (Severe Malaria):
  • Cerebral Malaria: Impaired consciousness, coma, seizures.
  • Severe Anemia: Hb < 7 g/dL (or < 8 g/dL with respiratory distress) due to hemolysis and dyserythropoiesis.
  • Acute Respiratory Distress Syndrome (ARDS): Tachypnea, dyspnea.
  • Hypoglycemia: Blood glucose < 2.2 mmol/L (40 mg/dL), especially with quinine treatment or high parasite burden.
  • Acute Kidney Injury: Elevated creatinine, reduced urine output.
  • Jaundice: Elevated bilirubin.
  • Shock: Hypotension, poor perfusion.
  • Hyperparasitemia: P. falciparum parasite density > 10% (WHO criteria vary, can be >2% or >5% in specific settings).
• Atypical Presentations: Pregnant women may present with atypical symptoms or have symptoms masked by pregnancy, leading to delayed diagnosis. Severe malaria can also occur with relatively low parasite densities in pregnant women.

Physical Examination

• Inspection: Pallor (suggesting anemia), jaundice, altered mental status, signs of respiratory distress (tachypnea, accessory muscle use), petechiae (coagulopathy).
• Palpation: Splenomegaly (common, but size may vary), hepatomegaly, tenderness in the abdomen.
• Special Tests:
  • Neurological Exam: For assessing level of consciousness, presence of meningism, or focal neurological deficits in suspected cerebral malaria.
  • Fundoscopy: Retinal changes (hemorrhages, whitening) can indicate cerebral malaria.
  • Fetal assessment: Fetal heart rate monitoring, uterine tenderness.

Diagnostic Approach

History Taking

• Key Questions:
  • Fever: Onset, duration, pattern, associated symptoms (chills, sweats).
  • Travel history: Recent travel to malaria-endemic areas (even brief layovers), or residence in an endemic area.
  • Previous malaria episodes: History of malaria, treatment, and response.
  • Pregnancy details: Gestational age, gravidity, parity, previous pregnancy outcomes.
  • Prophylaxis/Prevention: Use of ITNs, malaria chemoprophylaxis (for travelers), or IPTp (for residents).
  • Other symptoms: Headache, myalgia, fatigue, nausea, vomiting, abdominal pain, shortness of breath, altered mental status.
  • Comorbidities: Especially HIV status, which can influence severity and drug interactions.
• Red Flags: Any sign of severe malaria (altered consciousness, difficulty breathing, convulsions, severe pallor, significant bleeding), unremitting fever, persistent vomiting. These warrant immediate evaluation and treatment.

Laboratory Tests

• First-Line:
  • Microscopy (blood smear): The gold standard. Both thick and thin blood films should be performed.
    • Thick film: Detects the presence of parasites and quantifies parasite density (parasites per microliter of blood).
    • Thin film: Identifies the Plasmodium species and stage, crucial for treatment decisions.
    • Frequency: Should be performed immediately upon suspicion, and repeated every 12-24 hours to monitor treatment response in severe cases or until parasitemia clears.
  • Rapid Diagnostic Tests (RDTs): Detect specific malaria antigens (e.g., HRP2 for P. falciparum, pLDH for all species, or specific P. vivax antigens). Useful for rapid diagnosis, especially in remote areas lacking microscopy. A positive RDT should ideally be confirmed by microscopy where available, especially if species identification is critical or parasite density needs assessment.
• Confirmatory:
  • Repeat microscopy: If initial tests are negative but clinical suspicion remains high.
  • PCR (Polymerase Chain Reaction): Highly sensitive and specific, useful for confirming species, detecting mixed infections, or low-density infections not seen on microscopy. Usually reserved for reference laboratories or challenging cases.
• Monitoring:
  • Complete Blood Count (CBC): To assess for anemia (hemoglobin, hematocrit) and thrombocytopenia.
  • Blood Glucose: To detect and monitor hypoglycemia, especially with severe disease or quinine treatment.
  • Renal Function Tests: Serum creatinine, BUN.
  • Liver Function Tests (LFTs): Bilirubin, AST, ALT.
  • Electrolytes: To detect imbalances.
  • Arterial Blood Gas/Lactate: To assess for metabolic acidosis, especially in severe malaria.
  • Urinalysis: For hemoglobinuria (blackwater fever) or signs of kidney injury.
  • Fetal ultrasound: To assess fetal growth, amniotic fluid volume, and well-being.

Imaging

• Recommended: Generally not recommended for the primary diagnosis of malaria itself.
• Advanced:
  • Chest X-ray: If pulmonary complications (e.g., ARDS, pulmonary edema) are suspected.
  • Cranial CT or MRI: In cases of cerebral malaria with atypical neurological signs, focal neurological deficits, or if other causes of altered consciousness (e.g., hemorrhage, encephalitis) need to be excluded.
  • Abdominal Ultrasound: May be used to assess for splenomegaly or other abdominal complications.
  • Obstetric Ultrasound: Crucial for fetal monitoring, assessing gestational age, growth restriction, and amniotic fluid volume.

Management

Acute Management

• Immediate:
  • Assess severity: Rapidly determine if it's uncomplicated or severe malaria. Any sign of severity mandates immediate hospitalization and urgent treatment.
  • ABCs: Assess airway, breathing, circulation. Provide oxygen if hypoxic.
  • Fluid resuscitation: If dehydrated or in shock, but monitor carefully to avoid fluid overload, especially with pulmonary edema risk.
  • Correct hypoglycemia: Administer IV dextrose (e.g., 50 mL of 50% dextrose or 10% dextrose infusion) if blood glucose < 2.2 mmol/L (40 mg/dL).
• Stabilization:
  • Antipyretics: Administer paracetamol to control fever and discomfort.
  • Antiemetics: If vomiting prevents oral medication.
  • Monitor vital signs: Including blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation.
  • Fetal monitoring: Start continuous fetal heart rate monitoring and obstetric assessment.
• Emergency:
  • Severe Malaria (All Trimesters): Intravenous (IV) Artesunate is the treatment of choice due to superior efficacy and safety compared to quinine.
    • Dosage: 2.4 mg/kg IV on admission, then at 12 hours, 24 hours, and then daily until the patient can tolerate oral medication. A minimum of 3 doses should be given.
    • Rationale: Rapid parasite clearance, low toxicity.

Chronic Management

• Pharmacological (Antimalarials):
  • General Principles:
    • Prompt Treatment: Initiate treatment as soon as malaria is diagnosed.
    • Species-Specific Treatment: Tailor treatment to the infecting Plasmodium species.
    • Consider Resistance Patterns: Local drug resistance patterns guide treatment choice.
    • Drug Safety in Pregnancy: Select drugs with established safety profiles for the specific trimester.
    • Monitoring: Follow-up for treatment efficacy and adverse effects.
  • Uncomplicated P. falciparum Malaria (or mixed infections including P. falciparum):
    • First Trimester:
      • Preferred: Quinine sulfate (oral) 10 mg salt/kg body weight every 8 hours for 7 days, plus Clindamycin (oral) 10 mg/kg every 8 hours for 7 days.
        • Rationale: Quinine has a long history of use and is considered safe in the first trimester. Clindamycin adds efficacy and helps prevent recrudescence.
      • Alternative/If Quinine Not Tolerated/Available: Artemether-lumefantrine (AL).
        • Rationale: While ACTs are generally avoided in the first trimester due to limited safety data, the WHO and CDC acknowledge that if an ACT is the only effective treatment available or if severe malaria is likely without prompt, effective treatment, the benefits may outweigh the potential risks. AL is the most studied ACT in the first trimester. Administer standard 6-dose regimen over 3 days.
    • Second and Third Trimesters:
      • Preferred: Artemisinin-based Combination Therapies (ACTs) for 3 days. Examples:
        • Artemether-lumefantrine (AL): 80 mg artemether/480 mg lumefantrine fixed-dose combination, twice daily for 3 days.
        • Dihydroartemisinin-piperaquine (DP): Standard dose based on weight, once daily for 3 days.
        • Artesunate-amodiaquine (ASAQ): Standard dose based on weight, once daily for 3 days.
      • Rationale: ACTs are highly effective, well-tolerated, and considered safe in the second and third trimesters. They provide rapid parasite clearance and reduce the risk of recrudescence.
  • Uncomplicated P. vivax or P. ovale Malaria:
    • All Trimesters:
      • Preferred: Chloroquine 25 mg/kg total dose over 3 days (10 mg/kg stat, then 5 mg/kg at 6, 24, and 48 hours).
        • Rationale: Chloroquine is safe in all trimesters.
      • Alternative/Chloroquine Resistance: ACTs (as for P. falciparum).
      • Relapse Prevention (Hypnozoites): Primaquine and Tafenoquine are contraindicated in pregnancy due to the risk of hemolytic anemia in G6PD-deficient fetuses/neonates and lack of safety data. Relapses should be managed by repeated treatment with chloroquine or ACTs. Primaquine can be considered post-delivery if the mother is G6PD normal and not breastfeeding a G6PD-deficient infant.
  • Uncomplicated P. malariae or P. knowlesi Malaria:
    • All Trimesters: Chloroquine (as above).
    • Alternative/Chloroquine Resistance: ACTs (as above).
  • Severe Malaria:
    • All Trimesters: Intravenous (IV) Artesunate 2.4 mg/kg IV on admission, then at 12 hours, 24 hours, and then daily until the patient can tolerate oral medication (minimum 3 doses).
    • Follow-up: Once the patient can tolerate oral medication, complete a full course of an ACT (e.g., AL, DP, ASAQ) for 3 days. If an ACT is not available, quinine + clindamycin for 7 days can be used.
• Non-pharmacological:
  • Supportive Care: Good hydration, adequate nutrition, rest.
  • Correction of Anemia: Iron and folate supplementation after treatment. Blood transfusions for severe anemia (Hb < 7 g/dL or lower based on clinical stability).
  • Management of Complications: Address hypoglycemia, seizures, fluid/electrolyte imbalances.
• Monitoring:
  • Parasitemia: Daily blood smears until negative, then on Day 7, Day 14, Day 28, and weekly until Day 42 (if feasible) to detect recrudescence.
  • Clinical Status: Daily assessment of signs and symptoms, vital signs.
  • Laboratory Monitoring: Regular checks for anemia, hypoglycemia, renal/hepatic function, electrolytes, especially in severe cases.
  • Fetal Monitoring: Serial obstetric ultrasounds to assess fetal growth and well-being, especially for women with severe malaria or those treated in the first trimester. Regular fetal heart rate monitoring.

Treatment Algorithms

• First-Line:
  1. Suspected Malaria in Pregnant Woman: Obtain blood smear/RDT immediately.
  2. Uncomplicated Malaria:
     • P. falciparum or Mixed Infection:
       • 1st Trimester: Oral Quinine + Clindamycin (7 days). If not tolerated or unavailable, consider Artemether-lumefantrine (AL).
       • 2nd/3rd Trimesters: Oral Artemisinin-based Combination Therapy (ACT) for 3 days (e.g., Artemether-lumefantrine, Dihydroartemisinin-piperaquine, Artesunate-amodiaquine).
     • P. vivax, P. ovale, P. malariae, P. knowlesi: Oral Chloroquine (3 days). If chloroquine resistance or not available, use an ACT.
  3. Severe Malaria (Any Species, Any Trimester):
     • Initial: Intravenous Artesunate (2.4 mg/kg on admission, then 12h, 24h, then daily).
     • Follow-up: Once oral intake is possible, complete a 3-day course of an ACT.
• Second-Line:
  • If first-line treatment fails or is not tolerated:
    • Uncomplicated P. falciparum: Consider alternative ACT or quinine-based regimen. Consult with an infectious disease or malaria expert.
    • Uncomplicated P. vivax (Chloroquine Resistance): Use an ACT.
• Refractory Cases:
  • Re-evaluate diagnosis: Rule out misdiagnosis, mixed infection, or non-malaria fever.
  • Check for drug resistance: Consider sending samples for molecular testing if available.
  • Adherence: Assess patient adherence to the full drug regimen.
  • Consider alternative regimens: Under expert guidance.
  • Address underlying conditions: e.g., HIV co-infection, malnutrition.

Complications

• Common:
  • Maternal Anemia: Common due to hemolysis and dyserythropoiesis.
  • Preterm Birth: Increased risk.
  • Low Birth Weight (LBW): Due to IUGR and preterm birth.
  • Spontaneous Abortion/Stillbirth: Increased risk.
• Serious:
  • Maternal:
    • Severe Anemia: Requiring blood transfusion.
    • Cerebral Malaria: Encephalopathy, coma, seizures.
    • Acute Pulmonary Edema/ARDS.
    • Acute Kidney Injury.
    • Hypoglycemia.
    • Maternal Death.
    • Splenic Rupture (rare).
  • Fetal/Neonatal:
    • Intrauterine Growth Restriction (IUGR).
    • Congenital Malaria: Rare, but possible, especially with P. vivax.
    • Neonatal Death.
• Long-term:
  • Maternal: Chronic anemia, increased susceptibility to future infections.
  • Child: Developmental delays, increased susceptibility to infections, impaired cognitive development in children born to mothers with severe malaria.

Prognosis

• Factors:
  • Immunity status: Non-immune pregnant women (e.g., travelers, primigravidae) have a worse prognosis.
  • Parasite species: P. falciparum is associated with the worst outcomes.
  • Severity of disease: Severe malaria carries a significantly higher risk of complications and death for both mother and fetus.
  • Timeliness and effectiveness of treatment: Prompt, appropriate antimalarial therapy improves prognosis.
  • Gestational age: Early pregnancy infections may have different risks compared to late pregnancy.
  • Co-morbidities: HIV infection worsens prognosis.
• Survival:
  • Maternal mortality: Significantly increased with severe malaria, ranging from 10-50% depending on the severity and access to care. Uncomplicated malaria has low maternal mortality with prompt treatment.
  • Fetal mortality: High with severe maternal malaria, including increased rates of spontaneous abortion, stillbirth, and neonatal death.
• Quality of Life: Survivors may experience chronic anemia, fatigue, and for the infant, long-term neurodevelopmental or growth impacts from IUGR/preterm birth.

Prevention

• Primary: Preventing initial infection.
  • Vector Control:
    • Insecticide-Treated Bed Nets (ITNs): All pregnant women in endemic areas should sleep under ITNs.
    • Indoor Residual Spraying (IRS): Community-level intervention.
    • Environmental Management: Reducing mosquito breeding sites.
  • Chemoprophylaxis (for travelers):
    • For pregnant women traveling to malaria-endemic areas, effective chemoprophylaxis is crucial. Options include:
      • Mefloquine: Generally considered safe in the 2nd and 3rd trimesters, and may be used in the 1st trimester if exposure is unavoidable and benefits outweigh risks. (Weekly dosing).
      • Chloroquine/Hydroxychloroquine: Safe in all trimesters, but only effective in areas with chloroquine-sensitive malaria.
      • Atovaquone-proguanil and Doxycycline are generally avoided in pregnancy (doxycycline after 1st trimester due to fetal tooth discoloration, atovaquone-proguanil due to insufficient data).
      • Consult updated guidelines (CDC, WHO) for specific recommendations based on travel destination and trimester.
• Secondary: Early detection and intervention.
  • Intermittent Preventive Treatment in Pregnancy (IPTp) with Sulfadoxine-Pyrimethamine (SP):
    • WHO Recommendation: In areas of moderate-to-high P. falciparum transmission, IPTp-SP is recommended for all pregnant women.
    • Dosage: A single dose of SP (500 mg sulfadoxine + 25 mg pyrimethamine) orally.
    • Schedule: Administer at least 3 doses, starting as early as possible in the second trimester (from the 13th week of gestation), with each dose given at least one month apart.
    • Rationale: Prevents placental malaria, reduces maternal anemia, preterm birth, and low birth weight.
    • Contraindications: Known sulfa allergy, or if taking co-trimoxazole.
  • Prompt Diagnosis: Any febrile illness in a pregnant woman living in or returning from an endemic area should prompt immediate malaria testing.
• Tertiary: Preventing complications and long-term sequelae.
  • Complete Course of Treatment: Ensure adherence to the full antimalarial regimen.
  • Follow-up for Anemia: Iron and folate supplementation, monitoring Hb levels.
  • Fetal Monitoring: Regular ultrasounds to assess fetal growth and well-being.
  • Post-delivery care: Monitoring of mother and infant.

Special Populations

• Pediatric: Not applicable to this topic, but generally different drug doses and often different drug choices (e.g., primaquine in young children requires G6PD testing).
• Geriatric: Not applicable to this topic.
• Pregnancy: This entire document focuses on pregnancy. Key modifications include:
  • Increased susceptibility and severity of malaria.
  • Risk of placental malaria and adverse fetal outcomes.
  • Strict limitations on drug choices due to teratogenicity and fetal toxicity (e.g., primaquine, tafenoquine, tetracyclines, doxycycline are generally contraindicated).
  • Preference for Quinine + Clindamycin in the first trimester for uncomplicated P. falciparum.
  • Preference for ACTs in the second and third trimesters for uncomplicated P. falciparum.
  • IV Artesunate as the treatment of choice for severe malaria in all trimesters.
  • Importance of IPTp-SP in endemic areas.
  • Intensive maternal and fetal monitoring.
• Comorbidities:
  • HIV Co-infection:
    • Increased risk of severe malaria and higher parasite densities.
    • Potential for drug-drug interactions between antimalarials and antiretroviral therapies (ARTs). For example, some ACT components (e.g., lumefantrine, piperaquine) are metabolized by CYP3A4, which can be affected by certain ARTs (e.g., ritonavir-boosted protease inhibitors). Close monitoring is required.
    • IPTp with SP may interact with co-trimoxazole given for PCP prophylaxis; careful consideration and consultation are needed.

Clinical Pearls

• Diagnostic:
  • High Index of Suspicion: Always consider malaria in a febrile pregnant woman from or visiting an endemic area, regardless of perceived immunity.
  • Microscopy is Key: While RDTs are useful, always confirm with microscopy for species identification and parasite quantification, especially in pregnant women where management often depends on these details.
  • "Any fever, any time": For pregnant women in endemic areas, any fever should prompt a malaria test.
• Treatment:
  • Prompt Treatment Saves Lives: Do not delay treatment while awaiting confirmatory tests if clinical suspicion is high and severe malaria is a possibility.
  • IV Artesunate for Severe Malaria: This is a non-negotiable, life-saving intervention for severe malaria in any trimester.
  • Trimester-Specific Drug Choices: Carefully follow guidelines for drug selection based on gestational age to minimize fetal risk while maximizing maternal treatment efficacy.
  • No Primaquine in Pregnancy: Emphasize this contraindication due to G6PD deficiency risk.
  • IPTp is Critical: Advocate for and ensure eligible pregnant women receive appropriate IPTp-SP doses in endemic areas.
• Pitfalls:
  • Delay in Diagnosis/Treatment: Misattributing malaria symptoms to common pregnancy complaints (e.g., fatigue, nausea) can lead to severe disease.
  • Inappropriate Drug Selection: Using drugs contraindicated in pregnancy (e.g., primaquine, doxycycline after 1st trimester) or using a suboptimal regimen.
  • Failure to Monitor: Inadequate follow-up for parasitemia clearance, anemia, and fetal well-being.
  • Ignoring Complications: Missing signs of severe malaria or failing to manage complications (e.g., hypoglycemia, severe anemia) aggressively.
  • Assuming Immunity: Even multigravidae in endemic areas are susceptible, especially to placental malaria.

Recent Updates

• Guidelines:
  • The World Health Organization (WHO) continues to update its "Guidelines for the treatment of malaria." Recent updates have reinforced the recommendation for IV artesunate for severe malaria in all trimesters and have provided more nuanced guidance on ACT use in the first trimester where benefits outweigh risks.
  • CDC's "Guidelines for Malaria Prevention and Treatment in the United States" and specific recommendations for pregnant travelers are regularly updated.
  • The importance of three or more doses of IPTp-SP starting in the second trimester has been strengthened in areas of moderate-to-high transmission.
• Evidence:
  • Ongoing research confirms the safety and efficacy of ACTs in the second and third trimesters.
  • Studies are continuously evaluating the safety profile of ACTs in the first trimester, with increasing data supporting their use when the benefit clearly outweighs the potential risk, particularly where quinine is poorly tolerated or resistance is a concern.
  • Research on new antimalarial drugs and vaccines continues, though none are yet broadly available for specific use in pregnant populations.
• Controversies:
  • Use of ACTs in the First Trimester: While some guidelines are becoming more flexible, the debate continues regarding the optimal balance between efficacy, safety, and potential teratogenicity, especially in non-immune women or where resistance patterns necessitate ACTs. Quinine + clindamycin remains a safer, if less well-tolerated, option for uncomplicated P. falciparum in the first trimester.
  • Drug Resistance: The emergence of resistance to artemisinins in some regions (e.g., Southeast Asia) poses a significant challenge, necessitating vigilant monitoring and potential adjustment of treatment strategies globally.
  • Optimal IPTp Regimens: While SP is standard, research explores alternative drugs or combinations for IPTp in areas with high SP resistance.

Key References

• Guidelines:
  • World Health Organization (WHO): "Guidelines for the treatment of malaria." (Latest edition).
  • Centers for Disease Control and Prevention (CDC): "Malaria Diagnosis and Treatment in the United States" and "Malaria Prevention and Treatment for Travelers."
  • Royal College of Obstetricians and Gynaecologists (RCOG): "Malaria in pregnancy: Diagnosis and management."
  • Infectious Diseases Society of America (IDSA): "Clinical Practice Guidelines for the Diagnosis and Management of Malaria in the United States."
• Studies:
  • Dondorp AM, Fanello CI, Hendriksen IS, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657. (Landmark study for severe malaria treatment)
  • McGready R, Lee SJ, Wiladphaingern J, et al. Artemether-lumefantrine in pregnant women with uncomplicated falciparum malaria: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2008;8(10):609-618. (Safety and efficacy of ACTs in pregnancy)
• Reviews:
  • UpToDate: "Malaria in pregnancy: Treatment and prevention." (Regularly updated comprehensive reviews)
  • Cochrane Database of Systematic Reviews: Various reviews on antimalarials in pregnancy, IPTp.